Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 1/20 | 0.59 |
| ▸ | MGLL | Q99685 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21848101 | 1.00 | CPB1 (0.59) | CPB1MGLLKMT2AMEN1HSD11B1 | |
| SCHEMBL3723522 | 0.90 | ALDH1A1 (0.61) | KMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL2556107 | 0.89 | CPB1 (0.67) | CPB1MGLLKMT2AMEN1HSD11B1 | |
| Hydrochloric Acid SCHEMBL6998897 | 0.89 | ALDH1A1 (0.60) | KMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL1719734 | 0.88 | MGLL (0.68) | CPB1MGLLKMT2AMEN1HSD11B1 | |
| SCHEMBL5481329 | 0.87 | ALDH1A1 (0.65) | CPB1MGLLKMT2AMEN1HSD11B1 | |
| SCHEMBL22491508 | 0.85 | CPB1 (0.49) | CPB1MGLLKMT2AMEN1HSD11B1 | |
| SCHEMBL11349476 | 0.83 | KMT2A (0.54) | CPB1MGLLKMT2AMEN1HSD11B1 | |
| SCHEMBL21848140 | 0.81 | EPHX2 (0.44) | CPB1MGLLKMT2AMEN1HSD11B1 | |
| SCHEMBL21848139 | 0.81 | EPHX2 (0.44) | CPB1MGLLKMT2AMEN1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640242-B1 | ROCK-INHIBITING COMPOUND AND USES THEREOF | HITGEN LTD (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-11078161-B2 | Rock-inhibiting compound and uses thereof | HITGEN INC. (CN) | 2021-08-03 | — | — | US | disclosed |
| CN-109134367-B | Compound for inhibiting ROCK and application thereof | 成都先导药物开发股份有限公司 | 2020-10-02 | — | — | CN | disclosed |
| US-20200190035-A1 | ROCK-INHIBITING COMPOUND AND USES THEREOF | HITGEN INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3640242-A1 | ROCK-INHIBITING COMPOUND AND USES THEREOF | Hitgen Ltd. (CN) | 2020-04-22 | — | — | EP | disclosed |
| EP-2318362-A2 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | Theravance, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| US-7872028-B2 | Diaminopropanol renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| WO-2010011811-A2 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | VITAE PHARMACEUTICALS, INC. | 2009-07-23 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007117557-A2 | DIAMINOPROPANOL RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078161-B2 | Rock-inhibiting compound and uses thereof | ROCK1, ROCK2, RHOA | CPB1 2311/4885MGLL 3371/4885KMT2A 2008/4885 |
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | DNPEP, ACE, DPEP1 | CPB1 39/4885MGLL 772/4885KMT2A 1856/4885 |
| US-20200190035-A1 | ROCK-INHIBITING COMPOUND AND USES THEREOF | ROCK1, ROCK2, RHOA | CPB1 2311/4885MGLL 3371/4885KMT2A 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.